Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI

Human Brain Mapping

Volumn 33, Issue 11, 2012, Pages 2586-2602

  Holland, Dominic ^a   McEvoy, Linda K ^b   Dale, Anders M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid; Bias; Biomarker; Clinical trial; Disease specific effect; Entorhinal cortex; Hippocampus; MCI

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AGING; ALZHEIMER DISEASE; ALZHEIMERS DISEASE NEUROIMAGING INITIATIVE; ARTICLE; CALIBRATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; ENTORHINAL CORTEX; HUMAN; LABORATORY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEASUREMENT; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SAMPLE SIZE; TREATMENT RESPONSE;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; DATABASES AS TOPIC; DATABASES, FACTUAL; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; SAMPLE SIZE;

EID: 84863915683     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.21386     Document Type: Article

References (92)

1. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jr., Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW (2010): Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 6: 239-246.
2. Alexander GE, Chen K, Reiman EM (2010): adni_uaspmvbm_ dict_2010-05-23.csv. www.loni.ucla.edu/ADNI.
3. Ashburner J, Friston KJ (2000): Voxel-based morphometry-the methods. Neuroimage 11: 805-821.
4. Baker SG, Kramer BS (2003): A perfect correlate does not a surrogate make. BMC Med Res Methodol 3: 16.
5. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH (2010): The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement 6: 257-264.
6. Blennow K, Hampel H, Weiner M, Zetterberg H (2010): Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
7. Caroli A, Frisoni GB (2010): The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 31: 1263-1274.
8. Carrillo MC, Blackwell A, Hampel H, Lindborg J, Sperling R, Schenk D, Sevigny JJ, Ferris S, Bennett DA, Craft S, Hsu T, Klunk W (2009): Early risk assessment for Alzheimer's disease. Alzheimers Dement 5: 182-196.
9. Casella G, Berger RL (2002): Statistical inference. Australia; Pacific Grove, CA: Thomson Learning. xxviii, 660 p. p.
10. Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron JC (2005): Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27: 934-946.
11. Chetelat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC (2010): Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133: 3349-3358.
12. Christensen GE (1999): Consistent linear-elastic transformations for image matching. Information Processing in Medical Imaging, Proceedings 1613: 224-237.
13. Christensen GE, Johnson HJ (2001): Consistent image registration. IEEE Trans Med Imaging 20: 568-582.
14. Citron M (2010): Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398.
15. Cummings JL (2010): Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 31: 1481-1492.
16. Dale AM, Fischl B, Sereno MI (1999): Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9: 179-194.
17. Dale AM, Sereno MI (1993): Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction. Journal of Cognitive Neuroscience 5: 162-176.
18. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM (2009): Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371-380.
19. Fan Y, Batmanghelich N, Clark CM, Davatzikos C (2008): Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage 39: 1731-1743.
20. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002): Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33: 341-355.
21. Fischl B, Sereno MI, Dale AM (1999): Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 9: 195-207.
22. Fitzmaurice GM, Laird NM, Ware JH (2004): Applied longitudinal analysis. Hoboken, N.J.: Wiley-Interscience. xix, 506 p. p.
23. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM (2010): Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex 20: 2069-2079.
24. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM (2009): One-year brain atrophy evident in healthy aging. J Neurosci 29: 15223-15231.
25. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL (2005): Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology 64: 1032-1039.
26. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005): Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64: 1563-1572.
27. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN (2000): Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57: 339-344.
28. Freeborough PA, Fox NC (1997): The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 16: 623-629.
29. Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, Frosch MP, Hedley-Whyte ET, Locascio JJ, Lipsitz LA, Hyman BT (2008): Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol 67: 1205-1212.
30. Frisoni GB, Fox NC, Jack CR, Jr., Scheltens P, Thompson PM (2010): The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6: 67-77.
31. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005): Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562.
32. Hardy J, Selkoe DJ (2002): The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
33. Herrup K (2010): Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 30: 16755-16762.
34. Ho AJ, Hua X, Lee S, Leow AD, Yanovsky I, Gutman B, Dinov ID, Lepore N, Stein JL, Toga AW, Jack CR, Jr., Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2010): Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Hum Brain Mapp 31: 499-514.
35. Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM (2009): Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 20954-20959.
36. Holland D, Dale AM (2011): Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal 15: 489-497.
37. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008): Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223.
38. Hua X, Gutman B, Boyle CP, Rajagopalan P, Leow AD, Yanovsky I, Kumar AR, Toga AW, Jack CR, Jr., Schuff N, Alexander GE, Chen K, Reiman EM, Weiner MW, Thompson PM (2011): Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage 57: 5-14.
39. Hua X, Hibar DP, Lee S, Toga AW, Jack CR, Jr., Weiner MW, Thompson PM (2010): Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging 31: 1463-1480.
40. Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, Gutman B, Toga AW, Jack CR, Jr., Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2009): Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage 48: 668-681.
41. Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, Chou YY, Brun C, Chiang MC, Barysheva M, Jack CR, Jr., Bernstein MA, Britson PJ, Ward CP, Whitwell JL, Borowski B, Fleisher AS, Fox NC, Boyes RG, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander GE, Weiner MW, Thompson PM, Alzheimer's Disease Neuroimaging I (2008a): 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage 41: 19-34.
42. Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, Jack CR, Jr., Weiner MW, Thompson PM (2008b): Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage 43: 458-469.
43. Hyman BT (2011): Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. Arch Neurol.
44. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST (2008): Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131: 1630-1645.
45. Jack CR, Jr., Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, Decarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW (2010a): Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 6: 212-220.
46. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010b): Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
47. Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999): Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52: 1397-1403.
48. Jack CR, Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC (2004): Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62: 591-600.
49. Jack CR, Jr., Weigand SD, Shiung MM, Przybelski SA, O'Brien PC, Gunter JL, Knopman DS, Boeve BF, Smith GE, Petersen RC (2008): Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 70: 1740-1752.
50. Katz R (2004): Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1: 189-195.
51. Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV (2009): Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. Neuroimage 46: 786-802.
52. Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, Jack CR, Jr., Weiner MW, Thompson PM (2010): Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging 31: 1429-1442.
53. Kovacevic S, Rafii MS, Brewer JB (2009): High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 23: 139-145.
54. Leow AD, Yanovsky I, Chiang MC, Lee AD, Klunder AD, Lu A, Becker JT, Davis SW, Toga AW, Thompson PM (2007): Statistical properties of Jacobian maps and the realization of unbiased large-deformation nonlinear image registration. IEEE Trans Med Imaging 26: 822-832.
55. Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S (2010a): Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage 51: 1345-1359.
56. Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR, Jr., Weiner MW, Fox NC, Ourselin S (2010b): Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage 50: 516-523.
57. Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB (2010): Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 31: 1443-1451.
58. Mani RB (2004): The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 23: 305-314.
59. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR (2006): Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63: 38-46.
60. McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJ, Jr., Holland D, Koyama A, Brewer JB, Dale AM (2009): Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 73: 457-465.
61. McEvoy LK, Edland SD, Holland D, Hagler DJ, Jr., Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM (2010): Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord 24: 269-277.
62. McEvoy LK, Fennema-Notestine C, Roddey JC, Hagler DJ, Jr., Holland D, Karow DS, Pung CJ, Brewer JB, Dale AM (2009): Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251: 195-205.
63. McEvoy LK, Holland D, Hagler DJ, Jr., Fennema-Notestine C, Brewer JB, Dale AM (2011): Mild Cognitive Impairment: Baseline and Longitudinal Structural MR Imaging Measures Improve Predictive Prognosis. Radiology. 259: 834-843.
64. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991): The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
65. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010): APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131.
66. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L (2005): Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1: 55-66.
67. Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty J, Bartha R (2008): Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain 131: 2443-2454.
68. Perrin RJ, Fagan AM, Holtzman DM (2009): Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
69. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jr., Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010): Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74: 201-209.
70. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC (2001): Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58: 1395-1402.
71. Price JL, McKeel DW, Jr., Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009): Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30: 1026-1036.
72. Price JL, Morris JC (1999): Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-368.
73. Rabinovici GD, Jagust WJ (2009): Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 21: 117-128.
74. Reuter M, Rosas HD, Fischl B (2010): Highly accurate inverse consistent registration: a robust approach. Neuroimage 53: 1181-1196.
75. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006): Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet neurology 5: 828-834.
76. Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA, Harvey DJ, Jack CR, Jr., Weiner MW, Saykin AJ (2010): Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 31: 1401-1418.
77. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010): Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of aging 31: 1275-1283.
78. Salloway S, Mintzer J, Weiner MF, Cummings JL (2008): Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 4: 65-79.
79. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC (2010a): Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging 31: 1452-1462.
80. Schott JM, Bartlett JW, Fox NC, Barnes J (2010b): Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 68: 825-834.
81. Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Jr., Weiner MW (2009): MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132: 1067-1077.
82. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009): Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413.
83. Thompson WK, Holland D (2011): Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage 57: 1-4.
84. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR, Jr., Jagust W, Toga AW, Lee VM, Shaw LM (2010): Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6: 230-238.
85. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.
86. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, Knopman DS, Boeve BF, Petersen RC, Dickson DW, Jack CR, Jr. (2008): Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 42: 559-567.
87. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR, Jr., (2010): Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75: 143-151.
88. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Jr., (2009a): MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73: 287-293.
89. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Jr., (2009b): MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73: 294-301.
90. West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC (2004): Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 25: 1205-1212.
91. Yanovsky I, Leow AD, Lee S, Osher SJ, Thompson PM (2009): Comparing registration methods for mapping brain change using tensor-based morphometry. Med Image Anal 13: 679-700.
92. Yushkevich PA, Avants BB, Das SR, Pluta J, Altinay M, Craige C (2010): Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage 50: 434-445.